HHS: Medications for the Treatment of Opioid Use Disorder
Source
Federal Register
Link
Date
Feb 2, 2024
Summary
Notice of final rule from the U.S. Department of
Health and Human Services (HHS), Substance Abuse and Mental
Health Services Administration (SAMHSA) modifying and
updating certain regulatory provisions related to opioid
treatment program (OTP) accreditation, certification, and
standards for the treatment of opioid use disorder (OUD)
with medications for opioid use disorder (MOUD). These
changes include making flexibilities established during the
COVID-19 Public Health Emergency (PHE) permanent and
expanding access to care and evidence-based treatment for
OUD. This rule also removes all language and rules relating
to the Drug Addiction and Treatment Act (DATA) Waiver from
the regulations pursuant to the Consolidated Appropriations
Act, 2023. This rule is effective April 2, 2024, and the
compliance date is April 2, 2026.
Tagged as
Access · Accreditation · Healthcare business and finance · Illicit drug use · Legislation and regulations · Pharmacy and prescription drugs · Prescription drug misuse · Substance use and misuse